The biotech sector is booming with revenues for the entire industry reaching $64bn in 2012, in part thanks to capital markets. Kate Bingham, IBT investment manager and managing partner, SV Life Sciences Managers, explains why the sector's growth is not a bubble.
The biotechnology sector has grown spectacularly over the past five years since the global financial crisis. It has outperformed the S&P 500 index by over 100% in the five years to April 2013, with the NASDAQ Biotechnology index (“NBI”) growing 131% versus the S&P 500’s 29%. This is as a result of exciting new drugs and technologies being developed at record levels. With share prices surging, the biotechnology index has been catapulted to new highs above the “dotcom/genomics bubble”-era peak back in early 2000. As a result, investors are wondering whether we are in the midst of another...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
